Market Overview:
The global vecuronium bromide injection market is expected to register a CAGR of 5.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing number of surgical procedures and rising demand for neuromuscular blocking agents (NMBAs). In addition, growing geriatric population is also propelling the demand for vecuronium bromide injection globally. Based on type, the global vecuronium bromide injection market has been segmented into 10mg/vial and 20mg/vial. Among these, 10mg/vial segment is anticipated to account for a larger share in terms of revenue in 2018. This can be attributed to its lower price as compared to 20mg/vial type.
Product Definition:
A muscle relaxant used to produce short-term skeletal muscle relaxation during surgery or mechanical ventilation. It is a nondepolarizing neuromuscular blocker that competitively inhibits nicotinic acetylcholine receptors at the postsynaptic membrane.
10mg/vial:
Vecuronium Bromide Injection is used for the treatment of multiple sclerosis, spinal muscular atrophy and brain tumor. It works by blocking the action of a certain chemical (neurotoxin) that causes pain by triggering sensory nerves.
The global Vecuronium Bromide Injection market is expected to grow at a significant rate over the forecast period owing to its increasing demand in major markets such as Japan, Germany, France and Italy among others.
20mg/vial:
20mg/vial is a form of Vecuronium Bromide used for the treatment of post-polio syndrome, chronic pain, and neck pain. 20 mg/vial is administered through an intravenous infusion in the hospital or as a subcutaneous injection at home. The medication works by binding to voltage-gated ion channels that are responsible for transmitting signals between nerve cells in the brain. It also blocks sodium channels that are involved in generating neural activity and causing pain.
Application Insights:
The hospital application segment accounted for the largest share of over 50.0% in 2017. The increasing use of KRAS inhibitors as a standard therapy for advanced breast cancer is expected to drive demand from hospitals, which are likely to be the major buyers in near future. In addition, favorable reimbursement policies coupled with rising awareness regarding advanced treatment options are anticipated to further propel market growth during the forecast period.
Special clinics and recovery centers also held significant shares in 2017 and are expected to grow at a lucrative rate during the projected period owing to growing KRAS inhibitor adoption as an alternative therapy due largely oncology drugs by special clinics and recovery centers that offerKRAS inhibitoras part of their clinical trials programs along with other investigational drugs or therapies that have not been approved by U.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of hospitals and recovery centers, increasing healthcare expenditure, and high adoption rate for new technologies are some major factors contributing to the growth of this regional market. In addition, growing demand for non-invasive surgeries is also expected to drive the need for Vecuronium bromide injections over the forecast period.
Asia Pacific is expected to be one of fastest-growing regions during the forecast period owing to rising healthcare spending by governments as well as private sectors in order to improve patient care standards across various countries such as China and India.
Moreover, improving economic conditions will also contribute towards increased demand over time due to rise in disposable income which can be used towards purchasing expensive medicines required on a regular basis post-injection (i.e., ct scan or MRI).
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace. This will lead to an increase in the number of patients requiring Vecuronium Bromide Injection for medical purposes.
- Rising incidence of chronic diseases: The incidence of chronic diseases such as cancer, heart disease, and respiratory disorders is rising rapidly across the world. This will lead to an increase in the demand for Vecuronium Bromide Injection for treating these conditions.
- Growing popularity of neuromuscular blocking agents: Neuromuscular blocking agents are becoming increasingly popular due to their ability to provide muscle relaxation during surgery or other medical procedures. This will lead to an increase in demand for Vecuronium Bromide Injection globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Vecuronium Bromide Injection Market Research Report
By Type
10mg/vial, 20mg/vial
By Application
Hospital, Special Clinic, Recovery Center
By Companies
AuroMedics, Sun Pharma, Pfize, Teva, Mylan, Fresenius Kabi, Cisen Pharmaceutical, Chengdu Tiantaishan Pharmaceutical, Hainan Lingkang Pharmaceutical, Hainan Star Pharmaceutical, Jiangsu Nhwa Group, Shanxi Zhendong Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
229
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Vecuronium Bromide Injection Market Report Segments:
The global Vecuronium Bromide Injection market is segmented on the basis of:
Types
10mg/vial, 20mg/vial
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Special Clinic, Recovery Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AuroMedics
- Sun Pharma
- Pfize
- Teva
- Mylan
- Fresenius Kabi
- Cisen Pharmaceutical
- Chengdu Tiantaishan Pharmaceutical
- Hainan Lingkang Pharmaceutical
- Hainan Star Pharmaceutical
- Jiangsu Nhwa Group
- Shanxi Zhendong Group
Highlights of The Vecuronium Bromide Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10mg/vial
- 20mg/vial
- By Application:
- Hospital
- Special Clinic
- Recovery Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vecuronium Bromide Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Vecuronium bromide injection is a neuromuscular blocking agent used to temporarily stop the breathing of someone who is unconscious or otherwise unable to breathe on their own.
Some of the major companies in the vecuronium bromide injection market are AuroMedics, Sun Pharma, Pfize, Teva, Mylan, Fresenius Kabi, Cisen Pharmaceutical, Chengdu Tiantaishan Pharmaceutical, Hainan Lingkang Pharmaceutical, Hainan Star Pharmaceutical, Jiangsu Nhwa Group, Shanxi Zhendong Group.
The vecuronium bromide injection market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Vecuronium Bromide Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Vecuronium Bromide Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Vecuronium Bromide Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Vecuronium Bromide Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Vecuronium Bromide Injection Market Size & Forecast, 2020-2028
4.5.1 Vecuronium Bromide Injection Market Size and Y-o-Y Growth
4.5.2 Vecuronium Bromide Injection Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 10mg/vial
5.2.2 20mg/vial
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Special Clinic
6.2.3 Recovery Center
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Vecuronium Bromide Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Vecuronium Bromide Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 10mg/vial
9.6.2 20mg/vial
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Special Clinic
9.10.3 Recovery Center
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 10mg/vial
10.6.2 20mg/vial
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Special Clinic
10.10.3 Recovery Center
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 10mg/vial
11.6.2 20mg/vial
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Special Clinic
11.10.3 Recovery Center
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 10mg/vial
12.6.2 20mg/vial
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Special Clinic
12.10.3 Recovery Center
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 10mg/vial
13.6.2 20mg/vial
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Special Clinic
13.10.3 Recovery Center
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Vecuronium Bromide Injection Market: Competitive Dashboard
14.2 Global Vecuronium Bromide Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AuroMedics
14.3.2 Sun Pharma
14.3.3 Pfize
14.3.4 Teva
14.3.5 Mylan
14.3.6 Fresenius Kabi
14.3.7 Cisen Pharmaceutical
14.3.8 Chengdu Tiantaishan Pharmaceutical
14.3.9 Hainan Lingkang Pharmaceutical
14.3.10 Hainan Star Pharmaceutical
14.3.11 Jiangsu Nhwa Group
14.3.12 Shanxi Zhendong Group
